Table 1. Baseline cohort characteristics.
| Variable | Number (%) | Median | IQR |
| (N = 926) | |||
| Demographics | |||
| Gender | |||
| Female | 623 (67.3) | – | – |
| Male | 303 (32.7) | ||
| Age at start of ART (years) | |||
| 14–19 | 6 (0.6) | 38.3 | 32.1–44.6 |
| 20–29 | 135 (14.6) | ||
| 30–39 | 378 (40.8) | ||
| 40–49 | 299 (32.3) | ||
| 50–59 | 85 (9.2) | ||
| >60 | 23 (2.5) | ||
| Clinical/Immunological/Virological | |||
| BMI at start of ART (kg/m2) | |||
| <16 | 36 (3.9) | 20 | 18.5–22.0 |
| 16–18.5 | 219 (23.7) | ||
| >18.5 | 671 (72.5) | ||
| WHO stage at start of ART (n = 923) | |||
| Stage I | 43 (4.7) | – | – |
| Stage II | 156 (16.9) | ||
| Stage III | 548 (59.4) | ||
| Stage IV | 176 (19.1) | ||
| CD4 cell count at start of ART(cells/µL) (n = 919) | |||
| <100 | 335 (36.5) | 133 | 68–193 |
| 100–199 | 397 (43.2) | ||
| 200–299 | 148 (16.1) | ||
| 300–399 | 37 (4.0) | ||
| ≥400 | 2 (0.2) | ||
| Treatment | |||
| Initial ART combination | |||
| d4T 3TC NVP | 892 (96.3) | – | – |
| d4T 3TC EFV | 32 (3.5) | ||
| AZT 3TC NVP | 2 (0.2) | ||
| AZT 3TC EFV | 0 (0.0) | ||
| Median time on treatment (months) (n = 926) | |||
| Duration on ART | – | 38 | 33.8–45.0 |
IQR, interquartile range; ART, antiretroviral therapy; BMI, body mass index, ARV, antiretroviral drug.